Nippon Chemiphar Parts Ways With Ranbaxy, Takes Over Generics Venture
This article was originally published in The Pink Sheet Daily
Executive Summary
The June takeover of Ranbaxy by Daiichi Sankyo sparked speculation over whether the joint venture would end.
You may also be interested in...
Pfizer Leaps Into Japanese Generics Foray; Aims For 100 Generic Products By 2011
Pfizer's Established Products Business Unit, a branch in charge of invigorating off-patent drugs and leading generic drug activities, will establish commercial operations in Japan starting Dec. 1
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan
As Daiichi Sankyo Takes Over Ranbaxy Reins, Japan’s Nippon Chemiphar May Exit JV
MUMBAI - Ranbaxy and Nihon Pharmaceuticals, a subsidiary of Japan's Nippon Chemiphar, look set to end a joint venture they signed in 2002 to make an early entry into the Japanese generic market. That move is triggered due to a potential conflict of interest between Nippon Chemiphar and Ranbaxy's majority stakeholder Daiichi Sankyo in approaching the Japanese generic market